Lung cancer trials in Spain

In Spain 273 Also abroad 2733

273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 2/3Taking people
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Where
Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza
Age
18 years and over
People
500 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07100080
Phase 2Taking people
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
40 worldwide
Run by
Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Barcelona, Elche, Girona, Granada, Huelva, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Santiago de Compostela, Sevilla, Toledo, Torrejón de Ardoz, Valencia, Zaragoza
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2/3Taking people
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Where
Barcelona, Jaén, Jerez de la Frontera, Madrid
Age
18 years and over
People
550 worldwide
Run by
Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00
Phase 1/2Taking people
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Where
Barcelona, Cadiz, Granada, Jaén, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
162 worldwide
Run by
Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Barcelona, Madrid, Majadahonda, Zaragoza
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 2Taking people
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Where
Barcelona, L'Hospitalet de Llobregat, Pozuelo de Alarcón, Sevilla
Age
18 years and over
People
144 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00
Phase 1/2Taking people
Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)
Where
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia
Age
18 years and over
People
60
Run by
IDP Discovery Pharma S.L.
See details and how to joinNCT07864207
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Pamplona, Santander, Sevilla, Valencia
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 · EU 2024-518365-10-00
Phase 2Taking people
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Where
Barcelona, Jaén, Madrid, Málaga
Age
18 years and over
People
220 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT05967689
Phase 1/2Taking people
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga
Age
18 years and over
People
327 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Barcelona, Madrid, Málaga
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 1Taking people
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
180 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193
Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Barcelona, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia, Zaragoza
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1Taking people
A Study of ZW251 in Participants With Advanced Solid Tumors
Where
Barcelona, Logroño, Madrid, Málaga, Pamplona
Age
18 years and over
People
140 worldwide
Run by
Zymeworks BC Inc.
See details and how to joinNCT07164313
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Barcelona, Madrid, Rioja, Valencia
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Where
Barcelona, Logroño, Madrid
Age
18 years and over
People
124 worldwide
Run by
Pliant Therapeutics, Inc.
See details and how to joinNCT06270706
Phase 3Taking people
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Where
A Coruña, Badalona, Barakaldo, Barcelona, Córdoba, Girona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Marbella, Palma de Mallorca, Seville
Age
18 years and over
People
363 worldwide
Run by
OSE Immunotherapeutics
See details and how to joinNCT06472245
Phase 3Taking people
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Where
A Coruna, Badalona, Barcelona, Córdoba, Elche, Lleida, Madrid, Málaga, Móstoles, Reus, San Cristóbal de La Laguna, Santiago de Compostela, Sevilla, Torrejón de Ardoz, Valencia, Vigo, Zaragoza
Age
18 years and over
People
120 worldwide
Run by
Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Where
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón, Sevilla, Valencia, Vigo
Age
18 years and over
People
123 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06362252 · EU 2023-509629-36-00
Phase 1Taking people
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Where
Barcelona, Lleida, Madrid, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
392 worldwide
Run by
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00